Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JUVÉDERM VOLBELLA XC is a sterile, biodegradable, non-pyrogenic gel implant classified as an injectable dermal filler. It consists of cross-linked hyaluronic acid (HA) produced by Streptococcus species of bacteria at a concentration of 15 mg/mL and includes 0.3% lidocaine as a local anesthetic to reduce injection discomfort. The product is designed for injection into the lips for lip augmentation, correction of perioral rhytids (lines around the mouth), and improvement of infraorbital hollowing (undereye hollows) in adults over age 21. Its mechanism involves temporarily adding volume or fullness to targeted facial areas by integrating into the tissue matrix and attracting water molecules due to HA’s hydrophilic properties. Results typically last up to one year[1][2][3][4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on JUVÉDERM VOLBELLA XC.